#Pykus Therapeutics #PYK-2101 #retinal sealant

Pykus Therapeutics Expands Patent Portfolio for PYK-2101

Pykus Therapeutics, Inc., a pioneering medical technology firm based in Cambridge, Massachusetts, has recently made headlines with the announcement of a new patent for its promising retinal sealant, PYK-2101. This groundbreaking innovation aims to transform surgical practices for retinal detachment, a condition that can lead to significant visual impairment.

A New Era in Retinal Surgery

On February 26, 2025, Pykus disclosed that the United States Patent and Trademark Office has issued a new patent titled "Hydrogel Formulations and Methods and Devices for Administration of the Same" (U.S. Patent No. 12,233,157). This patent adds to Pykus' extensive intellectual property portfolio of over a dozen patents that safeguard their novel biomaterials targeted at treating various vitreoretinal diseases. With robust protections extending into 2044 for PYK-2101, Pykus is poised to make significant strides in addressing the critical needs of patients facing retinal surgeries.

Dr. Tommy Stryjewski, Chief Scientific Officer and co-founder of Pykus, expressed excitement over the patent issuance, calling it a significant step forward in addressing the shortcomings of current retinal surgical treatments. As clinical development programs expand, Pykus is committed to enhancing the healthcare landscape for patients blinded by eye diseases.

The Promise of PYK-2101

PYK-2101 stands out as a first-in-class biodegradable retinal hydrogel sealant. This innovative product promises to reshape the surgical landscape for retinal detachment procedures by dramatically enhancing patient experiences. Unlike traditional methods requiring the use of intraocular gases or silicone oil, PYK-2101 can seal retinal breaks directly without obstructing vision. This unique feature means that patients can avoid the uncomfortable